OmniAb Results Presentation Deck
We Plan to Continue to Innovate Around our Technology
THROUGH BUSINESS DEVELOPMENT AND INTERNAL INVESTMENT
Create Diverse
Antibody Repertoires
Create Diverse Repertoires of High-Quality
Naturally-Optimized Antibodies
Screen Antibody
Candidates
Launching new technologies this year
Screen Millions of Cells to Find
Potential Therapeutic Candidates
Identify the
Right Antibody
Further Characterize, Select &
Optimize the Right Antibody
Recently entered into an agreement with mAbsolve Ltd. for STR, mAbsolve's Fc-silencing platform technology. The
agreement provides OmniAb with exclusive, sublicensable right to incorporate the STR technology with antibodies
that have been generated using OmniAb's antibody discovery platform
11
OmniAbView entire presentation